Cargo Therapeutics (CRGX) said Wednesday that it will discontinue the phase 2 study of firicabtagene autoleucel, or firi-cel, for patients with large B-cell lymphoma, and reduce its workforce by about 50% to preserve cash for the development of other product candidates.
The company said results from an ad-hoc analysis of the phase 2 study data "do not support a competitive benefit-risk profile" of firi-cel for the target patient population. The company will focus instead on advancing CRG-023 and its allogeneic platform, while evaluating its strategic options.
Cargo Therapeutics said it targets to start enrollment for a phase 1 dose escalation study on CRG-023 in Q2.
Cargo Therapeutics shares were down more than 74% in recent premarket activity Thursday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.